Ablynx : ABLYNX ANNOUNCES WARRANT EXERCISE

                  Ablynx : ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION

GHENT, Belgium,  21 January  2013  - Ablynx  [Euronext Brussels:  ABLX]  today 
announced, in conformity with Title II of the Law of 2 May 2007 and the  Royal 
Decree of 14 February 2008, that an additional 61,812 common shares have  been 
issued by  the  Company in  exchange  for €329,619.51  as  the result  of  the 
exercise of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 43,779,197 shares outstanding.

About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and five Nanobodies at
clinical development stage. Ablynx has ongoing research collaborations and
significant partnerships with major pharmaceutical companies including
Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is
headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.

For more information, please contact

Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
 +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com

press release in pdf format

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Ablynx via Thomson Reuters ONE
HUG#1671922
 
Press spacebar to pause and continue. Press esc to stop.